HLA class, calcineurin inhibitor levels, and the risk of graft failure in kidney recipients with <i>de novo</i> donor-specific antibodies.

ABSTRACT:

Introduction

De novo donor-specific HLA antibody (dnDSA) are associated with poor outcomes. Whether this observation applies to both HLA class I and II dnDSA remains unclear.

Methods

We studied 1236 consecutive kidney recipients who had routine anti-HLA antibody surveillance post-transplant.

Results

During the screening period, 55/1236 (4.4%) patients developed dnDSA: 18 (33%) HLA-I only, 33 (60%) HLA-II only, and 4 (7%) both classes. Thirty patients experienced graft loss at a median of 39 months after dnDSA detection: 9/18 (50%) HLA-I only, 17/33 (52%) HLA-II only, and 4/4 (100%) both classes. A control group was created by matching patients with dnDSA to patients who did not develop DSA and had a functioning graft at the time of dnDSA detection in their respective

SUBMITTER: Beland MA 

PROVIDER: S-EPMC11614807 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature